

Pushing the Boundaries of Microsampling

Realising and Understanding the Full Potential

EBF Symposium 2014

Maryann Ngeny,
Senior Bioanalytical Scientist
Pre-Clinical Bioanalysis & Toxicokinetics, Alderley Park



The AstraZeneca Journey So Far....

Work pioneered by Ove Jonsson

Blood microsampling in routine use within Discovery functions

Transitioned from blood to plasma microsampling for toxicology evaluations

2007 - 2011

Definitive in-vivo data generated to support move to main study animals in GLP rodent toxicology studies

2012

Safety and DMPK leadership teams approve capillary microsampling in main study animals for use in regulatory facing non-GLP rodent toxicology studies

2013

TK sampling in rodents from main study animals for GLP and non-GLP studies

2014



Recap on Benefits of Microsampling

Macrosampling



Microsampling




- Causes less distress to animals during sampling
- Only one technician needed for blood sampling
- Lower costs - Fewer animal required per study & less test item used
- More TK sampling time-points feasible
- TK samples taken from main group animals - improved data quality



AZ approach to capillary microsampling

Sample collection and processing



* Water used as default diluent, but stabilisation agents can be added if required



So how far can we push?



- Smaller blood volumes ($< 32\mu\text{L}$)?
- Smaller plasma volumes ($< 8\mu\text{L}$)?
- Different blood processing methods?



Parameters to evaluate....

Blood volume

- What impact does reducing blood volume have on accuracy?

Sample Homogeneity

- Is analyte distribution homogeneous throughout plasma in capillary?

Plasma Volume

- Does plasma volume have an impact on quantification?

Haematocrit Level

- How does haematocrit level affect quantification in a plasma microsample?





Blood Processing

- Are alternative blood processing methods comparable to plasma microsampling?



Pushing the boundaries – Evaluation

Analytes Used




Tests carried out

- 20 μL vs 32 μL Blood
- 2x 4 μL vs 8 μL plasma
- Microsamples vs macrosamples
- 20, 40, 50 & 60% Haematocrit
- Blood/PBS vs plasma




Sample preparation methods used



Outcome of Evaluation...




Blood Volume & Sample Homogeneity



- Does blood volume have an impact on accuracy?
None observed; a 20 μL vs 32 μL blood sample are equivalent
- Is analyte distribution homogeneous throughout plasma in capillary?
Yes; 4 μL and 8 μL plasma microsamples are equivalent



Plasma volume




- Does plasma volume have an impact on quantification?
None observed; With the exception of Diclofenac, a micro and macrosample appear to be equivalent



Haematocrit Level

How does haematocrit level affect quantification in a plasma microsample?




Similar trends observed between micro & macro samples

Differences between haematocrit levels are more analyte-specific rather than technique related



Blood Processing



- Are alternative blood processing methods comparable to plasma microsampling?

Yes; there is potential to use blood dilution in place of plasma separation



Conclusions

Blood volume

- Use of a 20 μ L blood sample to generate 4 μ L plasma is viable (assay sensitivity dependent)

Sample Homogeneity

- Is not affected by using 4 or 8 μ L capillary microsamples as opposed to traditional macrosamples

Plasma Volume

- No significant differences in quantification between micro and macrosamples

Haematocrit Level

- Similar trends seen between micro and macro plasma samples. Differences between haematocrit levels not sampling technique related

Blood Processing

- There is potential to use PBS for dilution of a blood microvolume, but analyte blood partitioning and haematocrit level to be considered

Going forward.....

- **Perhaps carry out further tests on blood/ PBS and investigate the impact of haematocrit level as well as analyte blood/plasma partitioning properties on reproducibility?**



Acknowledgments

Amanda Wilson

Sara Viney (University of Leeds)

Kirsty-Jackson Addie

Michael Spreadborough

Teresa Collins



Thank you for listening

Any questions?



Confidentiality Notice

This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this file is not permitted and may be unlawful. AstraZeneca PLC, 2 Kingdom Street, London, W2 6BD, UK, T: +44(0)20 7604 8000, F: +44 (0)20 7604 8151, www.astrazeneca.com

